Details

Autor(en) / Beteiligte

• Rajda, Cecilia
• Rózsa, Csilla
• Mike, Andrea
• Lovas, Gábor
• Mezei, Zsolt
• Jakab, Gábor
• Ács, Péter
• Rum, Gábor
• Simó, Magdolna
• Jobbágy, Zita
• Bíró, Zita
• Trauninger, Anita
• Imre, Piroska
• Mátyás, Klotild
• Deme, István
• Illés, Zsolt
• Csepany, Tunde

Titel

Treatment of relapsing multiple sclerosis in Hungary - consensus recommendation from the Hungarian neuroimmunology society

Ist Teil von

• Orphanet journal of rare diseases, 2023-07, Vol.18 (1), p.183-183, Article 183

Ort / Verlag

England: BioMed Central Ltd

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Electronic Journals Library

Beschreibungen/Notizen

• Multiple sclerosis (MS) may impact quality of life, careers and family plans of the affected individuals. The current treatments with disease modifying therapies aim to prevent people with MS (pwMS) from disability accumulation and progression. Different countries have different reimbursement policies resulting in inequalities in patient care among geographical regions. Access to anti-CD20 therapies for relapsing MS is restricted in Hungary because therapy of individual cases only is reimbursed. In the light of the latest research and national guidelines, 17 Hungarian MS experts agreed on 8 recommendations regarding relapsing pwMS using the Delphi round method. Strong agreement (> 80%) was achieved in all except one recommendation after three rounds, which generated a fourth Delphi round. The experts agreed on treatment initiation, switch, follow-up and discontinuation, as well as on special issues such as pregnancy, lactation, elderly population, and vaccination. Well-defined national consensus protocols may facilitate dialogue between policymakers and healthcare professionals and thus contribute to better patient care in the long run.